Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Hepatitis Therapeutics Market Growth Potential: How Will Market Size Shift Through 2030?
The hepatitis therapeutics market size has experienced consistent growth in recent years. It is projected to increase from $19.08 billion in 2025 to $19.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.7%. The expansion observed in the historic period can be ascribed to the elevated occurrence of hepatitis B and C infections, the introduction of interferon-based therapies, broadened public vaccination initiatives, improved blood screening and diagnostic awareness, and government-led viral hepatitis control programs.
The hepatitis therapeutics market is anticipated to experience consistent expansion over the coming years. This market is projected to reach $23.43 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Several factors are expected to fuel this growth during the forecast period, including an increased adoption of direct-acting antivirals, greater investment in innovative immune modulators, enhanced treatment accessibility in developing markets, improved diagnosis rates resulting from screening initiatives, and advancements in pipeline development for pan-genotypic therapies. Key trends anticipated over the same period encompass a growing uptake of direct-acting antivirals for hepatitis C, a heightened emphasis on combination therapies for chronic hepatitis, the expansion of vaccination efforts aimed at hepatitis prevention, a move towards long-term management strategies centered on oral antivirals, and an increasing reliance on online and specialty pharmacies for accessing medications.
Get A Free Sample Report With In-Depth Market Insights:
Hepatitis Therapeutics Market Growth Backed By Core Demand Fundamentals
The increasing volume of clinical trials is projected to stimulate the expansion of the hepatitis therapeutic market moving forward. These trials are research studies designed to evaluate new treatments, medications, or interventions in human participants. They are critical in the evolution of new hepatitis therapeutics, establishing a robust and ethical framework to assess the safety and efficacy of potential treatments, which ensures that patients receive the most effective and beneficial therapies accessible. For instance, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, reported that the count of industry-initiated clinical trials in the UK rose from 411 trials in 2022 to 426 trials in 2023, representing a 3.7% increase. Thus, the escalating number of clinical trials is propelling the growth of the hepatitis therapeutics market.
Hepatitis Therapeutics Market Segment Analysis And Revenue Potential
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)
2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D, Hepatitis E
Hepatitis Therapeutics Market Growth Trends Reshaping The Competitive Landscape
Major companies operating in the hepatitis therapeutics market are concentrating on agreements to develop therapeutics, aiming to gain a competitive edge. A strategic agreement represents a formal contract between two or more parties, outlining the terms of their cooperation to achieve shared business goals. For instance, in October 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, announced an agreement to obtain an exclusive license for JNJ-3989. This compound is an investigational subcutaneous RNA interference (RNAi) therapeutic intended for the treatment of chronic hepatitis B (CHB). JNJ-3989 functions as a novel RNAi therapeutic that specifically targets the hepatitis B virus (HBV) X protein. The X protein is essential for both HBV replication and viral persistence.
Hepatitis Therapeutics Market Key Players Shaping Industry Direction
Major companies operating in the hepatitis therapeutics market are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Biocon Biopharmaceuticals Pvt. Ltd.
View The Full Hepatitis Therapeutics Market Report:
Hepatitis Therapeutics Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the hepatitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
